Navigation Links
EGFR protects cancer cells from starvation via a kinase-independent mechanism
Date:5/5/2008

Scientists have uncovered a previously unrealized mechanism by which the epidermal growth factor receptor (EGFR), a tyrosine kinase, promotes survival of cancer cells through a kinase-independent mechanism. The research, published by Cell Press in the May issue of the journal Cancer Cell, provides a rationale for the less than impressive results of recent clinical trials aimed solely at interfering with kinase activity and suggests new directions for potential therapeutic strategies.

The EGFR is closely associated with cell proliferation and survival and excessive expression, and activation of the EGFR is often observed in cancers of epithelial origin. Until now, it was believed that most of EGFRs functions were mediated by its kinase activity, and several compounds that specifically inhibit the kinase activity of the EGFR were developed with the aim of treating these cancers. However, the clinical experience so far has been that blockade of the EGFR tyrosine kinase activity alone does not elicit significant clinical outcomes in most patients.

The expression level of EGFR in cancer tissues is correlated with prognosis, but not with responsiveness to EGFR tyrosine kinase inhibitor treatment, suggesting that, independent of its kinase activity, EGFR may contribute to the progression of cancer, explains study author Dr. Isaiah J. Fidler from the Department of Cancer Biology at The University of Texas M.D. Anderson Cancer Center. Dr. Fidler and colleagues designed a series of studies to investigate the kinase-independent prosurvival function of the EGFR in cancer cells.

The researchers found that the EGFR enables human cancer cells to maintain adequate intracellular glucose levels by stabilizing the sodium/glucose transporter 1 (SGLT1) via a kinase-independent mechanism. Glucose is a major energy substrate for all cells, and without appropriate amounts, cells essentially starve to death through a process called autophagic cell death. Cancer cells are very active metabolically and consume more glucose than normal tissues; moreover, the EGFR overexpression and the associated enhanced stability of SGLT1 allow tumor cells to survive under conditions that would be less than optimal, even for normal cells.

Our results suggest that EGFR, independent of its kinase activity, maintains the basal intracellular glucose level and thereby prevents cancer cells from succumbing to autophagic death. It is possible that this function of the EGFR may even increase the survival capacity of cancer cells in the presence of chemotherapeutic agents, offers study author Dr. Mien-Chie Hung. The researchers suggest that inhibition of both EGFR-mediated SGLT1 stabilization and EGFR kinase activity may be necessary for eradication of epithelial tumors.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. What gives us sunburn protects crayfish against bacteria
2. Broccoli sprout-derived extract protects against ultraviolet radiation
3. Early HRT Protects a Womans Heart
4. Regular Walking Protects the Aging Brain
5. Ovary Removal Protects Some High-Risk Women
6. Cell recycling protects tumor cells from anti-cancer therapy
7. Fasting Before Chemo Protects Healthy Cells
8. Injectable Antibiotic Protects Against Lyme Disease in Mice
9. New Drug Protects Against Radiation Damage
10. Gene Variant Protects Black Heart Failure Patients
11. Treating Stomach Infection Early Protects Against Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... 25, 2017 , ... Back Pain Centers of America (BPC), which ... physician in their area, announces the launch of a new and proprietary customer relationship ... looking for reputable physicians to help them with back or neck pain and helps ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a ... its patient care management module. Using this new feature, sleep physicians can now ... initiated on continuous positive airway pressure (CPAP), oral, or other forms of sleep ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG CNS Healthcare ... Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national conference. , ... medical devices with a pre-programmed tablet in a remarkably easy-to-use kit for patients. ...
(Date:4/24/2017)... ... 24, 2017 , ... Ridgecrest Herbals makes it a point to lead the ... waste, and support renewable energy. They believe this is a crucial part of their ... for health issues, and maintain that destroying the environment in the pursuit of profit ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Research and Markets has ... and Market Prospects: Addressing Production Complexities Through Risk Management ... ... Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through ... assessment of the current trends in the global biosimilars ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
Breaking Medicine Technology: